NCT05469750Unknown2 期
A Single Arm，Multicenter，Open-label Study of Dalpiciclib Plus Letrozole and Capecitabine of First-line Treatment With High-risk HR- Positive /HER-2 Negative Advanced Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 48
- 主要终点
- ORR
研究概览
简要总结
to assess the effect of dalpiciclib plus letrozole and capecitabine of first-line treatment with breast cancer
详细描述
The purpose of the study is to assess the effect of dalpiciclib plus letrozole and capecitabine of first-line treatment with high-risk for HR- positive /HER-2 negative advanced breast cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age:18-75 years old, Postmenopausal or premenopausal/perimenopausal female;
- •HR-positive, HER2-negative breast cancer diagnosed by pathology, patients have evidence of focal recurrence or metastasis, are not suitable for curative surgical resection or radiotherapy, and have no clinical indications for chemotherapy.
- •ER positivity and/or PR positivity is defined as: the proportion of tumor cells with positive staining is ≥ 1% of all tumor cells (confirmed by the investigator of the trial center);
- •HER2-negative is defined as: 0/1+ by standard immunohistochemistry (IHC); HER2/CEP17 ratio less than 2.0 or HER2 gene copy number less than 4 by ISH (confirmed by the investigator of the trial center).
- •Patients must meet one of the following criteria:
- •≥2 organ metastases (internal organs)
- •Metastasis to a single organ (visceral organ) and meets at least one of the following criteria:
- •At least 2 or more measurable lesions
- •High histological/cytonuclear grade 3 as defined by the modified Bloom-Richardson grading system (also known as the Nottingham scale)
- •Ki67>30%
- •Simple bone metastases combined with ≥ 1 other recurrent metastatic site
- •No received any prior systemic anticancer therapy for focal recurrent or metastatic disease.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- •The main organs function well, and the inspection indicators meet the following requirements:
- •ANC≥1.5×109/L;
- •PLT≥100×109/L;
- •ALT and AST≤3×ULN, but≤5×ULN if the transferanse elevation is due to liver metastases；
- •TBIL≤1.5×ULN；
- •Serum creatinine ≤1.5×ULN;
- •There are measurable lesions meeting RECIST 1.1 criteria.
- •Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment and be willing to use a medically-approved high-efficiency contraceptive during the study period and within 3 months after the last dose of study drug.
- •All acute toxicities of previous antitumor therapy were relieved to grade 0-1 (according to NCI CTCAE version 5.0) or to the level specified by the inclusion/exclusion criteria. Other toxicities, such as alopecia, were excluded due to that the researchers believe do not pose a safety risk to patients.
- •Participants were willing to join in this study, and written informed consent.
排除标准
- •Patients with isolated bone metastases and/or brain metastases;
- •Diagnosed with any other malignant tumor within 3 years before entering the study, except for non-melanoma skin cancer, basal cell or squamous cell skin cancer or cervical carcinoma in situ after radical treatment.
- •Patients who were judged by the investigator to be unsuitable for endocrine therapy, including symptomatic, advanced patients with visceral dissemination who were at risk for short-term life-threatening complications (including uncontrolled massive exudates [thoracic, pericardial, abdominal], pulmonary lymphangitis, and more than 50% of patients with liver involvement)
- •The patient had previously received pyrimidine analogs and any CDK4/6 inhibitor.
- •Major surgery, chemotherapy, radiation therapy, any investigational drug, or other anticancer therapy within 2 weeks.
- •Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), active hepatitis B (HBV DNA ≥1000 IU/ml), hepatitis C (positive for hepatitis C antibody, and high HCV-RNA) the lower limit of detection of the analytical method) or co-infection with hepatitis B and C.
- •Within 6 months, the following conditions have occurred: myocardial infarction, severe/unstable angina, NYHA class 2 or higher cardiac insufficiency, sustained arrhythmia of ≥ class 2 (according to NCI CTCAE version 5.0), atrial arrhythmia of any class Fibrillation, coronary/peripheral artery bypass grafting, symptomatic congestive heart failure, cerebrovascular accident (including transient ischemic attack or symptomatic pulmonary embolism);
- •Complicated severe infection within 4 weeks before the first dose (eg: intravenous infusion of antibiotics, antifungal or antiviral drugs required according to clinical practice), or unexplained fever >38.5°C during screening/before the first dose.
- •Inability to swallow, intestinal obstruction, or other factors that affect drug administration and absorption.
- •Known hypersensitivity to letrozole, an LHRH agonist (goserelin), dalpiciclib, or any excipients.
- •Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
- •Known history of psychotropic substance abuse or drug use.
- •There are other serious physical or mental illnesses or abnormal laboratory tests that may increase the risk of participating in the study, or interfere with the results of the study, and patients who are considered unsuitable for participation in this study by the investigator.
研究组 & 干预措施
Dalpiciclib+ letrozole +capecitabine
Experimental
Dalpiciclib 150 mg was given orally once daily for 3 weeks, followed by 1 week off in each 4-week cycle.
letrozole 2.5mg po qd capecitabine 1000mg/m2 po bid
干预措施: Dalpiciclib+ letrozole +capecitabine (Drug)
结局指标
主要结局
ORR
时间窗: 24 month
Objective response rate
次要结局
- CBR(24 month)
研究者
相似试验
尚未招募
2 期
Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line ChemotherapyBreast CancerNCT05979220Shuangyue Liu178
已完成
1 期
Study Evaluating BLI-489 and Piperacillin in Healthy SubjectsHealthy SubjectsNCT00894439Wyeth is now a wholly owned subsidiary of Pfizer24
Unknown
2 期
Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid CarcinomaLung DiseasesThoracic NeoplasmsPulmonary Sarcomatoid CarcinomaNon-small Cell Lung CancerNCT04725448Sichuan Cancer Hospital and Research Institute27
已完成
1 期
Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic LeukemiaNCT03472573Sidney Kimmel Cancer Center at Thomas Jefferson University7
尚未招募
2 期
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI TherapyBreast CancerNCT05806671Tianjin Medical University Cancer Institute and Hospital30